Dr. Lal Path Labs Intrinsic Value
Dr. Lal Path Labs intrinsic value. Dr. Lal Path Labs (LALPATHLAB) median intrinsic value is ₹553.11 from 10 valuation models (range ₹369–₹922), vs current price ₹1843.70 — -70.0% downside (Trading Above Calculated Value), margin of safety -100.0%. For current market price and key ratios, visit Dr. Lal Path Labs stock price NSE.
LALPATHLAB Valuation Methods Summary — DCF, Graham Number & P/E
Dr. Lal Path Labs intrinsic value across 10 models vs current price ₹1843.70 — upside/downside and value range per method. Read Dr. Lal Path Labs dividend policy for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹553.11 | ₹442.49 - ₹663.73 | -70.0% | EPS: ₹31.44, Sector P/E: 12x |
| Book Value Method | asset | ₹368.74 | ₹331.87 - ₹405.61 | -80.0% | Book Value/Share: ₹151.25, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹553.11 | ₹497.80 - ₹608.42 | -70.0% | Revenue/Share: ₹173.10, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹737.48 | ₹663.73 - ₹811.23 | -60.0% | EBITDA: ₹844.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹737.48 | ₹589.98 - ₹884.98 | -60.0% | CF Growth: 9.2%, Discount: 15% |
| PEG Ratio Method | growth | ₹553.11 | ₹497.80 - ₹608.42 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹553.11 | ₹497.80 - ₹608.42 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹921.85 | ₹829.67 - ₹1014.04 | -50.0% | ROE: 20.8%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹553.11 | ₹497.80 - ₹608.42 | -70.0% | EPS: ₹31.44, BVPS: ₹151.25 |
| Dividend Yield Method | dividend | ₹585.71 | ₹527.14 - ₹644.28 | -68.2% | DPS: ₹20.50, Target Yield: 3.5% |
LALPATHLAB Intrinsic Value vs Market Price — All Valuation Models
Dr. Lal Path Labs fair value range ₹369–₹922 vs current market price ₹1843.70 across 10 valuation models. Compare with LALPATHLAB fair price to assess whether the stock is under or overvalued.
LALPATHLAB Intrinsic Value Analysis — Undervalued or Overvalued?
Dr. Lal Path Labs median intrinsic value ₹553.11, current price ₹1843.70 — Trading Above Calculated Value by 70.0%, margin of safety -100.0%.
What is the intrinsic value of LALPATHLAB?
Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Dr. Lal Path Labs (LALPATHLAB) is ₹553.11 (median value). With the current market price of ₹1843.70, this represents a -70.0% variance from our estimated fair value.
The valuation range spans from ₹368.74 to ₹921.85, indicating ₹368.74 - ₹921.85.
Is LALPATHLAB undervalued or overvalued?
Based on our multi-method analysis, Dr. Lal Path Labs (LALPATHLAB) appears to be trading above calculated value by approximately 70.0%.
LALPATHLAB Financial Health — Key Ratios vs Industry Benchmarks
Dr. Lal Path Labs financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 20.8% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 27.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.92x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
LALPATHLAB Cash Flow Quality — Operating & Free Cash Flow
Dr. Lal Path Labs operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹636 Cr | ₹425 Cr | Positive Free Cash Flow | 8/10 |
| March 2025 | ₹569 Cr | ₹418 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹535 Cr | ₹523 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹456 Cr | ₹313 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹447 Cr | ₹223 Cr | Positive Free Cash Flow | 7/10 |